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ABSTRACT. Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for
the validation of outcome measures for use in rheumatology clinical research. However, imaging and
biochemical measures may face additional validation challenges because of their technical nature.
The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the
iterative development of an imaging or biochemical measurement instrument so it can be used in
therapeutic assessment. 
Methods. A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an
imaging or biochemical measurement instrument: outcome domain(s), study setting, and
performance of the instrument. Movement along the axes in any dimension reflects increasing
validation. For a given test instrument, the 3-axis structure assesses the extent to which the
instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or
disease-centered variable, and whether its technical performance is adequate in the context of its
application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondy-
loarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the
newly proposed structure. Breakout groups critically reviewed the extent to which the candidate
biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the
proposed 3-dimensional structure.
Results. Although there was a broad acceptance of the value of the proposed structure in general,
some areas for improvement were suggested including clarification of criteria for achieving a certain
level of validation and how to deal with extension of the structure to areas beyond clinical trials. 
Conclusion. General support was obtained for a proposed tri-axis structure to assess validation of
imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place
within the OMERACT Filter 2.0. (First Release March 1 2014; J Rheumatol 2014;41:1016–24;
doi:10.3899/jrheum.131313)
Key Indexing Terms: 
BIOMARKERS                IMAGING                       OUTCOME AND PROCESS ASSESSMENT
OMERACT FILTER VALIDATION FRAMEWORK
From Versailles-Saint Quentin En Yvelines University, Department of
Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt,
France; Departments of Epidemiology and Biostatistics, and
Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands; University of Bristol, Academic Rheumatology Unit, Bristol
Royal Infirmary, Bristol, UK; Department of Rheumatology, Leiden
University Medical Center, Leiden, The Netherlands; Copenhagen Center
for Arthritis Research, Center for Rheumatology and Spine Diseases,
Copenhagen University Hospital Glostrup, Copenhagen, Denmark;
Department of Internal Medicine 3 and Institute for Clinical Immunology,
University of Erlangen-Nuremberg, Erlangen, Germany; Department of
Clinical Immunology and Rheumatology, Academic Medical Center,
University of Amsterdam and Atrium Medical Center, Amsterdam, The
Netherlands; Department of Medicine, University of Alberta, Edmonton,
Alberta, Canada; Department of Rheumatology, Hospital General
Universitario Gregorio Marañón, Madrid, Spain; Paris-Descartes
University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B,
Paris, France; Rheumatology Unit, Sapienza Università di Roma, Rome,
Italy; Division of Rheumatology, Johns Hopkins University, Baltimore,
Maryland, USA; University of Melbourne, Medicine, Dentistry and
Health Sciences, Melbourne, Australia; St. Michael’s Hospital, Mobility
Program Clinical Research Unit; Institute for Work and Health;
University of Toronto, Department of Health Policy, Management and
Evaluation, Department of Rehabilitation Science and Department of
Occupational Science and Occupational Therapy, Toronto, Ontario,
Canada; Pierre et Marie Curie University (UPMC) — Paris, GRC-UPMC
08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of
Rheumatology, Paris; Université de Lorraine, Université Paris Descartes,
EA 4360 APEMAC, Nancy and Inserm CIC-EC, CHU de Nancy, Nancy,
France; Department of Nursing, University of the West of England,
Bristol, UK; Swedish Medical Center and University of Washington,
Seattle, Washington, USA; Instituto Poal, Barcelona, Spain; SDG LLC,
Cambridge, Massachusetts; Birmingham Veterans Affairs Medical Center
and University of Alabama at Birmingham, Birmingham, Alabama;
 Journal of Rheumatology
The on October 31, 2016 - Published by www.jrheum.orgDownloaded from 
1017D’Agostino, et al: Imaging, biomarkers, and Filter 2.0
Division of Immunology/Rheumatology, Stanford University School of
Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and
Musculoskeletal Medicine, University of Leeds, and UK National Institute
for Health Research, Leeds Musculoskeletal Biomedical Research Unit,
Leeds, UK; Department of Epidemiology and Community Medicine, and
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
M-A. D’Agostino, MD, PhD, Versailles-Saint Quentin En Yvelines
University, Department of Rheumatology, Ambroise Paré Hospital,
APHP; M. Boers, MD, PhD, Departments of Epidemiology and
Biostatistics, and Rheumatology, VU University Medical Center; 
J.R. Kirwan, MD, University of Bristol, Academic Rheumatology Unit,
Bristol Royal Infirmary; D.M. van der Heijde, MD, PhD, Department of
Rheumatology, Leiden University Medical Center; M. Østergaard, MD,
PhD, DMSc, Copenhagen Center for Arthritis Research, Center for
Rheumatology and Spine Diseases, Copenhagen University Hospital
Glostrup; G. Schett, MD, Department of Internal Medicine 3 and Institute
for Clinical Immunology, University of Erlangen-Nuremberg; 
R.B. Landewé, MD, PhD, Department of Clinical Immunology and
Rheumatology, Academic Medical Center, University of Amsterdam and
Atrium Medical Center; W.P. Maksymowych, FRCPC, Department of
Medicine, University of Alberta; E. Naredo, MD, Department of
Rheumatology, Hospital General Universitario Gregorio Marañón; 
M. Dougados, MD, Paris-Descartes University, Medicine Faculty, APHP,
Cochin Hospital, Rheumatology B; A. Iagnocco, MD, Rheumatology Unit,
Sapienza Università di Roma; C.O. Bingham III, MD, Division of
Rheumatology, Johns Hopkins University; P. Brooks, MD, FRACP,
University of Melbourne, Medicine, Dentistry and Health Sciences; 
D.E. Beaton, BScOT, PhD, Department of Occupational Sciences and
Occupational Therapy, Institute for Health Policy Management and
Evaluation, University of Toronto; F. Gandjbakhch, MD; Laure Gossec,
MD, PhD, UPMC, GRC-UPMC 08 (EEMOIS); AP-HP Pitié Salpêtrière
Hospital, Department of Rheumatology; F. Guillemin, MD, PhD,
Université de Lorraine, Université Paris Descartes, EA 4360 APEMAC,
Nancy and Inserm CIC-EC, CHU de Nancy; S. Hewlett, PhD, RN,
Department of Nursing, University of the West of England; 
M. Kloppenburg, MD, PhD, Department of Rheumatology, Leiden
University Medical Center; P.J. Mease, MD, Swedish Medical Center and
University of Washington; I. Moller, MD, Instituto Poal; L.S. Simon, MD,
SDG LLC; J.A. Singh, MD, MPH, Birmingham Veterans Affairs Medical
Center and University of Alabama at Birmingham; V. Strand, MD,
Division of Immunology/Rheumatology, Stanford University School of
Medicine; R.J. Wakefield BM, MD, FRCP, Leeds Institute of Rheumatic
and Musculoskeletal Medicine, University of Leeds, and NIHR, Leeds
Musculoskeletal Biomedical Research Unit; G. Wells, Epidemiology and
Community Medicine; P. Tugwell, MD, Department of Medicine,
University of Ottawa; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP,
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of
Leeds, and NIHR, Leeds Musculoskeletal Biomedical Research Unit. 
Address correspondence to Prof. D’Agostino, Rheumatology Department,
APHP Ambroise Paré Hospital, 9 avenue Charles de Gaulle, 
92100 Boulogne-Billancourt, France. 
E-mail: maria-antonietta.dagostino@apr.aphp.fr
Imaging and biochemical tests are among the most rapidly
evolving fields within medicine1,2,3. In the last 30 years,
management of rheumatic diseases has been transformed by
the rapid expansion of sophisticated new technologies
offering a large range of options for identifying, monitoring,
and predicting pathological processes. Unfortunately many
of these new measurement instruments have been dissemi-
nated into daily practice before being rigorously evaluated
and have in some cases already been employed as endpoints
in randomized clinical trials (RCT) evaluating therapeutic
interventions. The subsequent validation of imaging
methods and biochemical tests may be difficult to achieve a
priori, owing to their already established use in clinical
settings. 
The Outcome Measures in Rheumatology (OMERACT)
initiative has worked on validating tools for evaluating the
effect of therapeutic interventions in rheumatic diseases
since 19924. Its main goal is to achieve consensus over what
should be measured and how, especially for developing the
most appropriate outcomes for use in RCT. The process
involves choosing a core domain set to measure within a
particular condition and in a particular clinical setting, and
the application of the OMERACT Filter of truth, discrimi-
nation, and feasibility to evaluate identified candidate
instruments to measure these domains, which result in a
validated core outcome set5. This framework, especially as
further developed in preparation for the OMERACT 11
meeting6, particularly addresses the importance of appro-
priate identification of the domains, subsequent selection of
appropriate instruments, and the correct methodology for
developing and validating the instruments for their purpose.
However, imaging and biochemical measures may face
additional validation challenges because of their technical
nature. These challenges might be thought of as equivalent
to the technical processes in the development of patient
reported outcomes, as addressed in another session of the
meeting7. 
For imaging and soluble biomarkers, there are important
questions to address: (1) whether the measure relates to the
suspected pathophysiological change [e.g., whether erosions
on radiographs of the hands identify the same process as
lesions on magnetic resonance imaging (MRI) scans or
whether urinary biochemical measure relates directly to
cartilage damage in knee osteoarthritis (OA)]; (2) whether
the measure has an agreed and consistent procedure (e.g.,
whether radiographs of the knees should always be taken
with the patient standing); and (3) to what extent operator
expertise is a prerequisite (e.g., in the acquisition and inter-
pretation of ultrasound images of synovitis). 
At the OMERACT 11 meeting, the Imaging and
Biomarker Work Stream presented a draft proposal in which
aspects of technical and measurement validity could be
expressed and validated at the same time. It was the group’s
intention to provide a step-by-step guide for development of
an imaging or biochemical measurement instrument such
that it could then be used as an outcome in RCT or as a
useful tool for clinical practice (manuscript in preparation).
This would serve a similar purpose to the clear statements
now available on the technical requirements for developing
PRO. By considering the currently available evidence for
the validity of various imaging and biochemical measures, it
should be possible to identify their current level of
achievement according to the original OMERACT Filter
requirements. In a plenary introduction, M-A. D’Agostino
proposed a hierarchical structure, reflecting 3 dimensions
needed for validating an imaging or biochemical
measurement instrument: (a) outcome domain(s), (b) study
setting, and (c) performance of the instrument. By using
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these 3 axes of evaluation, it should be clearly defined
whether a given instrument is able to measure the domain of
interest (for example, whether it is a measure of disease
activity, of damage, of both, or of another aspect of the
pathological process); whether it assesses a disease or
patient-centered variable (for example, if it measures the
activity of the disease at joint level, or it is an expression of
the disease activity at patient level); whether its technical
performance is adequate, including its feasibility, and
whether the instrument has reached the appropriate
validation state relevant to the given purpose (for example,
whether it can be used as a biomarker or as a patient
outcome). The global validation level reached by the
biological or imaging variable under evaluation and its
usefulness for OMERACT purposes would thus be
described by its position relative to all 3 axes. 
During OMERACT 11, the ideas underlying the
framework for validating imaging or biochemical instru-
ments as outcome measures in therapeutic trials underwent
preliminary consensus-based development. At the same
time, some experts in the field of arthritis and imaging and
soluble biomarkers presented the current state of validation
of a number of chosen instruments in a range of rheumatic
diseases, in light of the original OMERACT Filter and of the
newly proposed structure. 
Discussion Groups
OMERACT 11 attendees were divided into disease-related
subgroups: rheumatoid arthritis (RA); spondyloarthritis
(SpA); and knee OA. In each subgroup, the domain of
measurement (disease activity, irreversible damage, or both)
and the technical performance and validation state of several
currently available imaging or soluble biomarkers were
presented by experts in the subgroup field (RA: D. van der
Heijde, M. Østergaard, and G. Schett; SpA: R. Landewé, W.
Maksymowych, and E. Naredo; knee OA: P. Conaghan, M.
Dougados, and A. Iagnocco). The biomarkers varied
between subgroups as shown in Table 1. Following these
presentations, each subgroup was divided into smaller
discussion groups (about 20 participants each, including 2
patient partners), who were then asked to consider the
questions presented in Table 1, and in particular to consider
how the biomarkers performed in relation to the emerging
description of OMERACT Filter 2.06 and the proposed new
hierarchical structure. Each discussion group reported its
main points to a plenary session of all participants. 
Imaging and Soluble Biomarkers in RA 
With respect to RA, participants agreed that structural
damage depicted by radiography fulfilled most aspects of
the former OMERACT Filter of truth, discrimination, and
feasibility8,9, and it was recognized that semiquantitative
assessment of erosions and joint space narrowing (JSN)
were currently accepted as structural outcomes for RCT10,11.
Erosions, bone edema, and synovitis depicted by MRI have
been shown to cover all aspects of truth12,13,14,15,16,17, and
the RA MRI score (RAMRIS) for erosions, bone edema, and
synovitis has also demonstrated responsiveness and discrim-
ination18,19,20,21,22. Although feasibility issues such as
accessibility, time, cost, and patient compliance may cause
limitations in clinical practice, MRI is acceptable for clinical
trials. This is further supported by the fact that MRI has
been used in an increasing number of RCT, and participants
agreed that MRI provides valid outcomes (activity and
severity/damage). However, it was pointed out that
further information is required from an RCT setting to
understand the relationship between MRI outcomes and
subsequent radiographic progression. With respect to
soluble biomarkers, C-reactive protein (CRP) has been
demonstrated to be sensitive to change and to fulfill
most of the aspects of truth for therapeutic purposes, but
it has not been shown to always predict future disease
severity23,24,25,26,27. For the other proposed soluble
biomarkers in RA few data are available, and they will
require further validation28,29,30,31,32,33,34,35,36,37,38,39,40. 
Imaging and Soluble Biomarkers in SpA 
Until recently, imaging and soluble biomarkers have
focused on their relationship to radiographic structural
change in SpA41,42. In the breakout groups, there was
consensus that there was also an unmet need for validated
biomarkers reflecting inflammation in SpA, with the crucial
caveat that while validation of a damage biomarker
measured by radiography has face validity and feasibility,
discussion continues on a feasible imaging or biochemical
biomarker measure for the target domain of inflammation.
Certain data suggest the utility of MRI for this purpose. MRI
of the spine and sacroiliac joints using bone marrow edema
(BME) as an inflammatory variable has been assessed using
the former OMERACT Filter and 2 instruments prioritized
for scoring BME in the spine, the SpondyloArthritis
Research Consortium of Canada and Berlin spinal inflam-
mation scores43,44,45,46,47,48 as useful tools for evaluating
inflammation. Validation was undertaken principally from
the perspective of feasibility and discrimination but not
completely for truth. There was agreement in the breakout
groups that MRI represented the best currently available
imaging measure for the target domain of inflammation,
despite limited longitudinal data between inflammation at
baseline and changes after institution of tumor necrosis
factor-a blocker therapies49,50,51,52. No soluble biomarker
for inflammation in SpA was considered to have met the
requirements of the OMERACT Filter, and therefore for
being used as an outcome measure53. Unlike in RA, CRP
and erythrocyte sedimentation rate are increased in only half
of patients with SpA who have active disease52, and
therefore are not broadly applicable measures of inflam-
matory activity. An increasing number of soluble
 Journal of Rheumatology
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Table 1. Summary of presentation of 3 disease groups: rheumatoid arthritis (RA), spondyloarthritis (SpA), and knee osteoarthritis (OA).
Disease Group Measurement Unit of What are the outcome Validation Reached Is the chosen instrument/
Instrument Measurement domains currently measure validated enough for
covered by the instrument? being considered an outcome 
measure and included in a 
core set of outcomes? 
RA Radiographs Joint (hands Structural damage (erosion, Most of the scoring methods Erosion/JSN as combined
and feet) JSN) of erosions and JSN have scoring system has been
been demonstrated to fulfill measured in many RCT and has 
all aspects of validity. been considered critical for both
Can be considered as patient evaluating efficacy and guiding 
outcome in RCT, observational evaluation and treatment. It
studies, and in clinical care has been demonstrated to be a 
good prognostic outcome of 
severity and mortality, and it has 
been used as a surrogate for 
patient outcome in observational 
studies. Therefore it is used also 
in the context of patient outcome
in usual clinical care
MRI Joint (hand) Disease activity  The RAMRIS scoring method Synovitis/osteitis good candidate
(synovitis, osteitis) for synovitis/osteitis has been outcome measures: 
demonstrated to fulfill face, prognostication+++, sensitivity
construct, and some aspects of to change+++
discrimination validity, and to 
be predictive of future 
radiographic damage. Feasibility 
was suggested by its use in 
multiple large RCT
Structural damage The RAMRIS scoring method Erosion: Good possible candidate 
(erosion, JSN) for erosions has been for severity and damage; 
demonstrated to fulfill face, JSN: Possible candidate 
construct, and some aspects of for severity and damage
discrimination validity. These 
data support further evaluation 
of erosion as candidate outcome 
measure (surrogate of radiographic 
structural damage) for future trials. 
The RAMRIS scoring method for 
JSN has been demonstrated to 
fulfill face and construct validity. 
These data support further 
evaluation of JSN as candidate 
outcome measure for future trials
Soluble  Patient (blood) Disease activity CRP has been demonstrated to This measure has been used in
biomarkers fulfill all aspects of validity but many trials and has been 
some aspects of discrimination considered critical for both
remain a problem. It is also evaluating efficacy and severity 
considered a good indicator for 
future severity and mortality
Damage/severity (ACPA, Some biomarkers are clearly Only prediction of future 
cleavage products, matrix related to structural radiographic radiographic damage was
metalloproteinase 3, progression and severity demonstrated.
calprotectin and receptor (e.g., ACPA, MMP3) and some Further validation is needed 
agonist of nuclear factor have demonstrated change in 
B ligand) accordance with radiographic 
progression (MMP3). However, 
further validation is needed before 
using them as candidates outcome 
measures for future interventional trial
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2014. All rights reserved.
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Table 1. Continued.
Disease Group Measurement Unit of What are the outcome Validation Reached Is the chosen instrument/
Instrument Measurement domains currently measure validated enough for
covered by the instrument? being considered an outcome 
measure and included in a 
core set of outcomes? 
SpA MRI Joint (axial-SIJ, Disease activity (bone Several scoring methods at SIJ Bone marrow edema
spine) marrow edema) and spine levels have been as quantified by SPARCC spine
demonstrated to fulfill face and SIJ and Berlin spine MRI 
validity and discrimination). scores are excellent candidate
Feasibility not widely examined. outcome measures for disease
Noted that MRI is considered to activity. Not validated for 
be quite good for diagnostic structural damage
purposes (i.e., presence of sacroiliitis)
Structural damage (bone marrow Preliminary data for bone Further data needed from
edema, erosions, fat lesions) marrow edema and fat lesions longitudinal and interventional studies
Ultrasound Joint (peripheral Disease activity (synovitis, Detection of synovitis has been Possible good candidate, but no
enthesis) enthesitis) demonstrated to be valid but yet data available
sensitive to change in RCT. 
Detection of enthesitis has been 
demonstrated to fulfill some aspects 
of truth and discrimination (including 
sensitivity to change) but not in RCT. 
Feasibility remains a problem
Structural damage (erosions, Truth aspect demonstrated for No data available
enthesophytes, calcifications) erosions and enthesophytes. 
Sensitivity to change/
responsiveness not yet demonstrated. 
No data available in RCT
Soluble  Patient (blood) Disease activity, systemic CRP has been demonstrated to CRP usually used in RCT, but 
biomarkers inflammation (CRP, IL-6) fulfill face validity, some aspect lack of representation in all
of construct and discrimination patients with active disease
validity, and also to be weakly 
predictive of future radiographic damage. 
Damage/severity (MMP3) Not enough data available for Only prediction of future radiographic 
suggesting extensive use, or being damage was demonstrated  
tested in clinical trials 
Knee OA Radiographs Joint Structural damage (JSN, JSN fulfills all aspects of validity, JSN already accepted in core set
osteophytes) reliability related to acquisition  of OA trials from previous
technique. Noted that JSN in used OMERACT recommendations 
in clinical decision making
MRI Joint Disease activity (synovitis, Synovitis, effusion have Recommendations from OARSI
effusion) criterion, reliability, and suggest cartilage measures should
responsiveness data, as well as be included as a primary outcome 
predictive validity for severe measure in structure modification 
progression (knee replacement) trials. More RCT data required. More
data from RCT required on other 
biomarkers such as bone measures
Structural damage (cartilage, Cartilage morphology is the most 
bone, menisci, ligaments) studied feature and is valid. Bone 
marrow lesions have criterion and 
discrimination (reliability and some 
data on responsiveness) validity and 
also to be predictive of future 
structural damage
Ultrasound Joint Disease activity (synovitis,  Detection of synovitis and Possible good candidates, 
effusion) effusion has demonstrated but no data available
validity but not in RCT. Both 
detection of synovitis and effusion 
have been demonstrated for severe 
progression (knee replacement)
Structural damage (cartilage Validity demonstrated for both Possible good candidates, 
loss, osteophytes) cartilage loss (limited anatomical but no data available 
view acknowledged) and osteophytes. 
No data available as outcomes 
candidates in RCT
JSN: joint space narrowing; RCT: randomized controlled trials; MRI: magnetic resonance imaging; RAMRIS: Rheumatoid Arthritis MRI Score; OARSI: OA
Research Society International; SIJ: sacroiliac joint; CRP: C-reactive protein; IL-6: interleukin 6; MMP3: matrix metalloproteinase-3; ACPA: anticitrullinated
protein antibodies; SpA: spondyloarthritis; SPARCC: SpondyloArthritis Research Consortium of Canada; OMERACT: Outcome Measures in Rheumatology.
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biomarkers have been analyzed for their potential associ-
ation with radiographic progression in SpA [matrix metallo-
protease 3 (MMP3), Dickkopf-1, sclerostin, etc.], for
example, MMP3 is significantly associated with this
endpoint and it is now under further evaluation54,55,56,57,58.
Among imaging techniques, ultrasound was considered an
interesting candidate for assessing SpA enthesitis as a
marker of inflammatory activity both at site specific
(entheses) and patient levels59,60,61,62,63. 
Imaging and Soluble Biomarkers in Knee OA 
Because OA may have joint-specific issues, participants
agreed that limiting the discussion to knee OA, where there
are the most data, was appropriate. In terms of RCT, JSN on
conventional radiography has been demonstrated to fulfill
validity requirements, although the relationship between
symptoms and structural damage measures is com-
plex64,65,66. The ability to identify patients who may sub-
sequently benefit from joint replacement is difficult to
determine because of several contributory factors including
that the decision to undertake surgery, despite clinical
symptoms, is determined by multiple issues such as
healthcare access, individual surgeon, and patient factors
(including comorbidities). An OMERACT/Osteoarthritis
Research Society International working group has proposed
criteria for a “virtual” joint replacement outcome given
these factors67,68. Previous OMERACT recommendations
have included plain radiographs as an outcome measure in a
core set for structural modification in OA69,70. There has
been considerable growth in the use of MRI and ultrasound
in this field, with much emerging data71,72,73,74,75. The
ability to measure multiple tissue pathologies has
high-lighted that structure modification studies may focus
on only 1 tissue of interest. MRI cartilage morphometry is
the most studied outcome and has demonstrated evidence
(summarized in recent reviews) to fulfill the requirements of
the OMERACT Filter, although some feasibility issues
remain73,74,75. Data are accumulating on measures of other
tissue pathologies. 
Broader Understanding Stimulated by Discussion 
There was widespread recognition among the groups that
many imaging and soluble biomarkers have been widely
introduced into clinical practice and used in interventional
therapeutic trials without adequate evaluation of their
performance. Although access to healthcare and technology
varies considerably, the presentation of the proposed 3 axes
of evaluation provided participants with a structure that
allows them to consider the place of imaging and other
soluble biomarkers in the broader healthcare setting, beyond
the OMERACT traditional focus on RCT. There was strong
agreement that a checklist (or standardized framework)
would be very helpful for imaging and soluble biomarker
development and validation. This standardized approach has
already been used in other fields79. There is also potential
for linking imaging and biomarkers with PRO. OMERACT
has already started to work toward criteria for validation of
soluble biomarkers and surrogates in general76,77,78. The
new tridimensional structure incorporates previous work
and extends the concept of development also to imaging
biomarkers. This could provide an appropriate reference
standard to make measure development issues clearer
(fixing an objective and a research agenda), but it may not
be feasible for all candidate instruments/biomarkers because
it may be difficult to achieve all levels of validation in
particular circumstances. However, the early recognition
that a specific biomarker would never achieve validation at
some critical levels may prevent unnecessary efforts toward
further validation. It was also discussed that fulfillment of
the OMERACT Filter 2.0 would be a prerequisite for justi-
fiable use of biomarkers in routine clinical interventional
trials; but in circumstances where many are already in
widespread use, participants favored the explicit devel-
opment of the requirements as presented but incorporating
some modifications and clarifications. 
While the 3 disease-related subgroups each brought to
light specific points related to their particular areas of evalu-
ation (Table 1), 2 common issues related to the proposed
axes of evaluation emerged. The first was the need for
clarity on the notion of a hierarchical structure to these axes.
Would it be possible to satisfy performance criteria on 1 or
more axes without being able to do so on others? The second
was whether the use of an outcome measure already applied
in clinical practice for diagnosis or prognosis might be justi-
fiable also for therapeutic interventional trials even if that
measure has not been shown to meet the OMERACT Filter
for use in RCT and longterm observational studies.
The OMERACT 11 meeting examined the proposed
Filter 2.0 framework of core areas, core domains, and
contextual factors, which had already been subject to
discussion and development before the meeting. At the same
time, the meeting provided a focus for updating each aspect
of the filter (truth, discrimination, and feasibility) and the
application of the former and the new filter in terms of
imaging and soluble biomarkers in this session. There was
broad recognition that many imaging techniques and
biomarkers widely used in clinical practice were used for
evaluating therapeutic interventional trials without having
been adequately validated. It would be worth working to
more clearly state their use (i.e., whether an imaging or
biomarker instrument measures disease activity, irreversible
damage, or both), whether their technical performance is
adequate, as well as their level of validation, including feasi-
bility. Such a standardized approach will need to be clarified
and addressed further within Filter 2.0.
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